NA
TXMD icon

NewEdge Advisors’s TherapeuticsMD TXMD Stock Holding History

NewEdge Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$1 – 4379
2025
Q3 		$1 Hold
1
– – ﹤0.01% 4092
2025
Q2 		$1 Sell
1
-2
-67% -$2 ﹤0.01% 3981
2025
Q1 		$3 Hold
3
– – ﹤0.01% 3935
2024
Q4 		$3 Buy
+3
New +$4 ﹤0.01% 3891

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewEdge Advisors's TXMD Position: Q4 2025 in Review

NewEdge Advisors sold out of TherapeuticsMD (TXMD) in Q4 2025, closing a stake of 1 share — an estimated $1 sold.

NewEdge Advisors first reported a position in TXMD in Q4 2024 and held it in 4 quarters. The position peaked at $3 in Q1 2025. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.

  • NewEdge Advisors reported no remaining TherapeuticsMD position as of Q4 2025 after selling out during the quarter.
  • NewEdge Advisors sold 1 TherapeuticsMD share in Q4 2025, an estimated $1.
  • NewEdge Advisors first reported a position in TherapeuticsMD in Q4 2024 and held it in 4 quarters.
  • NewEdge Advisors's TherapeuticsMD position peaked at $3 in Q1 2025.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.

Based on NewEdge Advisors's 13F filing for Q4 2025, filed 18 Feb 2026.